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ABSTRACT  
Objective: The aim of the study was to evaluate the bioequivalence between a newly developed generic tablet containing fixed-dose combination of 
amlodipine besylate, valsartan and hydrochlorothiazide (10/160/25 mg), and the reference brand product Exforge HCT®
Methods: The brand (reference) and the test (generic) products were administered to thirty-nine healthy subjects. A fasting, laboratory blind, 
single-dose, two-treatment, two-period, two-sequence, randomized crossover design was conducted with 14 d washout period between dosing. 
Serial blood samples were withdrawn from each subject immediately before dosing (zero time), and then at 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 
3.5, 4.0, 5.0, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 14, 16, 24, 48 and eventually at 72 h post dosing. Plasma samples were analyzed for 
simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by a newly developed HPLC coupled with MS/MS detector. The 
linearity of the method was established for plasma concentration ranges of 0.2-12 ng/ml, 50-8000 ng/ml, and 2-250 ng/ml for amlodipine, 
valsartan, and hydrochlorothiazide, respectively.  
 tablet; using a newly 
developed HPLC-MS/MS method for simultaneous determination of these drugs in human plasma.  
Results: Plasma concentration-time data of each individual were analyzed by non-compartmental method to measure the pharmacokinetics 
parameters; Cmax, Tmax, AUC0-t, AUC0-∞, λZ, T1/2. For amlodipine truncated AUC72hr was calculated. The 90% confidence interval for the pharmacokinetic 
parameters used for bioequivalence evaluation (Cmax and AUC) for amlodipine, valsartan, and hydrochlorothiazide were well within FDA acceptable 
ranges of 80-125%.  
Conclusion: It is concluded that the newly devolved generic product is bioequivalent with the brand product Exforge HCT®
Keywords: Amlodipine, Valsartan, Hydrochlorothiazide, Pharmacokinetics, Bioequivalence, HPLC-MS/MS 
 tablet. Thus, both 
products are clinically interchangeable.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Exforge HCT® is a brand film-coated tablet formulated for oral 
administration in five strengths which are available in the market as 
fixed dose combinations of 5/160/12.5 mg, 10/160/12.5 mg, 
5/160/25 mg, 10/160/25 mg, and 10/320/25 mg of amlodipine 
besylate, valsartan, and hydrochlorothiazide. The maximum 
recommended dose of Exforge HCT® is 10/320/25 mg. Exforge 
HCT®
Exforge HCT
 tablets are produced by Novartis, Switzerland, and approved 
by FDA on April 30, 2009 [1].  
® hypertension is indicated for the treatment of . The 
three components; amlodipine, valsartan, and hydrochlorothiazide 
lower blood pressure through complementary mechanisms, each 
working on a separate site and blocking different effector pathways. 
Many patients require more than one drug to achieve blood pressure 
goals, such as patients with diabetes or hyperlipidemia, and such 
patients would be expected to benefit from more aggressive 
treatment to lower blood pressure. Some antihypertensive drugs 
have smaller blood pressure effects when given as monotherapy, 
therefore, selection of combination therapy is recommended [1]. 
The active ingredients of Exforge HCT® target three separate 
mechanisms involved in blood pressure regulation. Specifically, 
amlodipine blocks the contractile effects of calcium on cardiac and 
vascular smooth muscle cells. Valsartan blocks the vaso-
constriction and sodium retaining effects of angiotensin 
Several studies indicated that dual therapy with amlodipine and 
valsartan achieved significantly greater reduction in blood pressure 
than monotherpay by amlodipine or valsartan [1-3]. Additionally, 
many clinical studies demonstrated that triple therapy with 
amlodipine, valsartan, and hydrochlorothiazide in a single tablet 
contributes additional advantages to fixed dose combinations of two 
drugs by achieving higher and more rapid reduction in blood 
pressure in safe and well-tolerated manner [4-10]. Besides, the 
effectiveness is maintained over the entire 24 h dosing period [6]. 
The most frequent adverse effects of Exforge HCT
II on 
cardiac, vascular smooth muscle, adrenal and renal cells. 
Hydrochlorothiazide directly promotes the excretion of sodium 
and chloride in the kidney leading to reductions in intravascular 
volume [1].  
® that occurred in 
controlled clinical trial in at least 2% of patients treated with a 
maximal dose (10/320/25 mg of amlodipine/v alsartan/ 
hydrochlorothiazide) are; dizziness, edema, headache, dyspepsia, 
muscle spasms, fatigue, back pain, nasopharyngitis [1]. It cannot be 
determined whether these events were causally related to Exforge 
HCT® [1]. The triple fixed dose combination is well tolerated and 
most adverse events are transient and of mild to moderate severity 
[2-10]. Furthermore, the use of double [11] or triple [12] fixed 
dose 
No clinically relevant pharmacokinetic drug interactions were 
reported between 
combinations that reduce pill burden could help the patients to 
continue treatment, decreased total healthcare costs and medication 
compliance and adherence, and consequently result in improved 
clinical outcomes in hypertensive patients [11, 12].  
amlodipine, valsartan, and hydrochlorothiazide in 
triple combination [13]; and the corresponding double combination 
valsartan, and hydrochlorothiazide [14]. Besides, clinically 
significant interactions were not observed between the individual 
components; amlodipine [15, 16], valsartan [17-20], or hydro-
chlorothiazide [21, 22] and other drugs.  
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Following oral administration of Exforge HCT® tablet to normal 
healthy adults; peak plasma concentrations of amlodipine, valsartan, 
and hydrochlorothiazide are reached in about 6 h, 3 h, and 2 h, 
respectively. The rate and extent of absorption of individual dosage 
forms of amlodipine, valsartan or hydrochlorothiazide are similar to 
the triple fixed combination tablets (Exforge HCT®). The 
bioavailability of amlodipine, valsartan, and hydrochlorothiazide 
was not altered when Exforge HCT®
The absolute bioavailability of amlodipine in monotherapy has been 
estimated to be between 64%-90%, and the apparent volume of 
distribution is about 1500 L. After oral administration of 5, and 10 
mg amlodipine besylate tablets, the maximum plasma was found to 
be about 3, and 6 ng/ml, respectively. The time to reach peak 
concentration ranged 6-12 h. The drug is approximately 93% bound 
to plasma proteins, and it is extensively (about 90%) converted to 
inactive metabolites via hepatic metabolism. The elimination of 
amlodipine from the plasma is biphasic with a terminal elimination 
half-life of about 30 to 50 h [23-38]. Amlodipine tablet was found to 
be bioequivalent to amlodipine solution [24], amlodipine capsule 
[30], amlodipine orodispersible tablet [30], or amlodipine 
suspension [38]. 
 was administered with food, 
therefore, it may be administered with or without food [1]. 
The absolute bioavailability of valsartan in monotherapy is about 
25% (range 10% to 35%), and the steady-state volume of 
distribution of after intravenous administration is 17 L indicating 
that valsartan does not distribute into tissues extensively. The drug 
is highly bound to serum proteins (95%), mainly serum albumin. 
After oral administration of 160 mg valsartan tablet, the maximum 
concentration of the drug in plasma range from 2000-6000 ng/ml, 
which achieved within 2 to 4 h. The drug shows biexponential 
decay kinetics following intravenous administration with an average 
terminal elimination half-life of about 6 h, and 6-9 h after oral intake. 
Valsartan is mainly excreted unchanged with only about 20% of the 
dose recovered as metabolites [27-29, 39-42]. 
The absolute bioavailability of hydrochlorothiazide as monotherapy 
is about 70%, and the concentration of the drug is reached after 2 to 
5 h of drug intake. There is no clinically significant effect of food on 
the bioavailability of hydrochlorothiazide. The drug binds to 
albumin (40% to 70%) and distributes into erythrocytes. 
Hydrochlorothiazide concentrations decline biexponentially, with a 
mean distribution half-life of about 2 h and an elimination half-life of 
about 10 h, about 70% of an orally administered dose of 
hydrochlorothiazide is eliminated in the urine as unchanged drug 
[42-44]. 
Several analytical methods are available for individual 
determination of amlodipine, valsartan, hydrochlorothiazide, or the 
corresponding double and triple fixed dose combinations in bulk 
powder and pharmaceutical dosage forms [45-55]. On the other 
hand, many bioanalytical methods are found for monitoring plasma 
concentrations of amlodipine, valsartan, or hydrochlorothiazide 
administered as monotherapy, or as the corresponding double fixed-
dose combination [56-59]. However, recently a bioanalytical method 
is presented for simultaneous determination of plasma 
concentrations of amlodipine, valsartan and hydrochlorothiazide in 
triple fixed dose combination for pharmacokinetic, bioavailability, 
and bioequivalence studies [13].  
As per international guidance, documentation of bioequivalence are 
considered as pivotal and crucial part for registration of generic 
drug products since bioequivalence studies are conducted to show 
that the rate and extent of bioavailability of the generic product are 
identical to the brand product. Consequently, the effect(s) and side 
effect(s) of the generic product are essentially equivalent to the 
brand product, and hence both products are considered 
interchangeable in clinical practice [60-64].  
The present investigation was aimed to conduct a comparative 
bioavailability (bioequivalence) study between, a newly developed 
generic tablet containing fixed-dose combination of amlodipine 
besylate, valsartan, and hydrochlorothiazide (10/160/25 mg), and 
the reference brand product (Exforge HCT®
MATERIALS AND METHODS 
 tablet, produced by 
Novartis, Switzerland), applying FDA guidance on bioavailability and 
bioequivalence [60, 61]; by utilizing a newly developed HPLC-
MS/MS method for simultaneous determination of amlodipine, 
valsartan and hydrochlorothiazide in plasma applying FDA 
bioanalytical method validation guidance [65].  
Study products  
Reference product: Exforge HCT®
Test product: a newly developed generic tablet containing fixed 
combination of amlodipine besylate, valsartan, and hydro-
chlorothiazide (10/160/25 mg). 
 tablet, produced by Novartis, 
Switzerland, containing fixed-dose combination of amlodipine 
besylate, valsartan, and hydrochlorothiazide (10/160/25 mg). 
Ethical considerations 
The study was conducted according to the provisions of the 
declaration of Helsinki [66], and ICH guidelines for good clinical 
practice [67]. The subjects provided written and signed informed 
consent before the commencement of the study. As per the above-
mentioned guidelines, the study protocol was written, and then 
approved by the principal investigator, clinical investigator, 
Institutional Review Board (IRB), the sponsor, and eventually the 
local health authority before conducting the study. For ethical 
considerations, the subjects were free to leave the study for any 
reason and at any time. Moreover, according to the clinical 
investigator's decision, subject’s withdrawal at any time during the 
study was also considered to protect the health of the subjects.  
Study design 
As per study protocol, the study was designed as; fasting, laboratory 
blind, single-dose, two-treatment, two-period, two-sequence, 
randomized crossover design with 14 d washout interval between 
period I and period II dosing. Forty subjects enrolled in the study. An 
equal number of subjects (20 subjects) were randomly assigned to 
each dosing sequence of the test and the reference formulations [60-
64].  
Inclusion criteria 
Forty male adult subjects were selected from the pool of the Jordan 
Center for Pharmaceutical Research, Amman, Jordan. The subjects 
were judged healthy and considered eligible for participation in the 
study based on the following inclusion criteria: age between 18-50 y; 
normal body mass index 18.5-30{BMI=weight (kg)/height2 (meter); 
nonsmokers or light smokers (less than 10 cigarette per day); no 
drug or alcohol abuse; no history of contraindication and/or allergy 
to the investigational drugs; physical and clinical examinations 
including normal vital signs, renal, hepatic, cardiovascular/ECG, 
pulmonary, gastrointestinal, neurological and psychiatric; normal 
clinical laboratory tests including biochemistry, hematology, routine 
urine analysis, negative HIV, hepatitis B and C; no clinically 
significant illness within 4 w before the start of the study; no 
concomitant intake or administration of any prescribed systemic or 
topical medications within 2 w prior to the study conduct; the 
subjects have not been participated in another trial (clinical, 
pharmacokinetic, bioavailability or bioequivalence) within the last 2 
mo prior the study; no treatment with drugs known to alter the 
major metabolic systems within the last 30 d of starting the study; 
no major surgery; no donation of blood or plasma within the last two 
months of the study; the supine blood pressure (after resting for 5 
min) is not higher than 140/90 or lower than 110/70 mmHg; the 
supine pulse (after resting for 5 min) is not outside the range of 60-
90 beats/min; not vegetarian; and there is no evidence of 
uncooperative attitude of the subject. 
Study conduct 
The subjects attended the clinical site at about 6:00 p. m. the day 
before drug products dosing and remained confined (hospitalized) 
in the clinical site until 24 h post-dosing. Alcohol abuse test and drug 
abuse tests were performed during admission to exclude any subject 
with positive result. Before administration of study medication, the 
principal or the clinical investigator with the aid of nurses checked 
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the label against the randomization schedule to ensure that the 
subject number on the label corresponds to the number allocated to 
each recipient. The drug product (the test or the reference) was 
administered with 240 ml of water after an overnight fasting of 10 h. 
Hand check and mouth check were achieved in order to insure that 
the drug was taken by the subject as directed. No water was allowed 
1 hour before and 1 hour after dosing. Standard diets (breakfast, 
lunch and dinner) were served after 4, 9, and 14 h, respectively post 
dosing. The diets were identical in both periods of the study. 
Xanthine-containing drinks were not allowed 7 d before dosing till 
the follow-up examination. Grapefruit juice or beverages containing 
grapefruit were not allowed within the past week before the study 
and until the completion of the study (end of period II). The subjects 
were remained seated upright and not allowed to sleep or lie during 
the first six hours of drug administration. At the end of period II, 
clinical examinations including clinical laboratory tests, ECG and vital 
signs were performed for each subject before subjects discharge. 
Blood sampling 
Serial blood samples were collected from each subject via an 
Indwelling cannula placed into the forearm anticubital vein for the 
first 24 h post dosing to avoid multiple skin puncture, whereas, the 
rest blood samples were collected using direct vein puncture by 
disposable syringe. The cannula was kept patent by flushing with 1 
ml of heparinized saline (2 IU per ml) after each blood sample 
withdrawal. Besides, before each blood sampling withdrawal, about 
0.2 ml of blood was discarded from the cannula to get rid of residual 
blood from previous sampling. Blood was sampled immediately 
before drug product administration (zero/blank sample), and then 
at 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 6.5, 7.0, 7.5, 
8.0, 8.5, 9.0, 9.5, 10, 11, 12, 14, 16, 24, 48 and eventually at 72 h post 
dosing. A total of 28 blood samples were obtained from each subject 
in each period. Blood samples were immediately placed in a 
heparinized tube, shacked gently, and then centrifuged for 5 min at 
4000 rpm to separate the plasma. The plasma samples were stored 
at-20º C until analysis for simultaneous determination of 
amlodipine, valsartan and hydrochlorothiazide. All tubes used for 
blood and plasma samples were labeled by confidential coding 
system according to in-house standard operating procedures of the 
research unit. The principal investigator and the quality assurance 
responsible only have the excess of the labeling system.  
Clinical observations  
Vital signs (blood pressure and pulse) were recorded few minutes 
before drug product administration, and then at 0.5, 1.0, 1.5, 2.0, 2.5, 
3.0, 3.5, 4, 6, 8, 10, 12, 14, 16, 24 and eventually at 72 h post 
administration. The adverse events (if any), were registered by the 
clinical staff at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 24, 48 and 72 
h post drug product administration. All clinical observations were 
followed for each subject and for each test and reference drug 
product. The adverse events and serious adverse events if any were 
recorded based on vital signs, clinical observations, and direct 
questioning. For follow-up, clinical laboratory tests, ECG and vital 
signs were done before and then after period II.  
Drugs bioanalysis 
A new HPLC-MS/MS method was developed and validated in Jordan 
Center for Pharmaceutical Research, Amman, Jordan for 
simultaneous determination of amlodipine, valsartan and hydro-
chlorothiazide in human plasma. The method was validated 
according to FDA and EMEA bioanalytical method validation 
guidance [62, 65]. Amlodipine was detected in plasma in the range of 
0.2-12 ng/ml with a lower limit of quantification (LLOQ) of 0.2 
ng/ml. Valsartan detection range was 50-8000 ng/ml with LLOQ of 
50 ng/ml. Hydrochlorothiazide detection limit was 2-250 ng/ml 
with LLOQ of 2 ng/ml.  
Amlodipine with its internal standard amlodipine-d4, valsartan with 
its internal standard valsartan-d3, and hydrochlorothiazide with its 
internal standard hydrochlorothiazide–d2 c13 were extracted from 
human plasma samples by liquid-liquid extraction technique. 
Samples were analyzed by reversed-phase liquid chromatography 
coupled with MS/MS detector. As per FDA and EMEA guidance [62, 
65], the validation include; selectivity, lower limit of quantification 
(LLOQ), calibration range, accuracy, precision, matrix effects, 
stability of the analytes (amlodipine, valsartan and hydro-
chlorothiazide) in the biological matrix (plasma), and stability of the 
analytes and of the internal standards in the stock and working 
solutions and in extracts under the entire period of storage and 
processing conditions.  
The materials used in this study include the following: The HPLC 
system was Agilent, model: 1200 series, USA. The detector was 
applied biosystems, MDS SCIEX, model: API 4000, USA. The 
computer system was windows 7 professional. The data 
management software was Analyst 1.6. The micropipettes were 
Eppendorf 20-200 µl, and 100-1000 µl, USA. The dispenser was 
Eppendorf 2-10 ml, USA. The centrifuge was Eppendorf, model: 5702 
R, USA. The analytical balance was Sartorius, model: ME235S, 
Germany. The freezer was Frigidaire-20 ºC, USA. The refrigerator 
was Daewoo 2-8 °C, Korea. 
The HPLC was optimized according to the following 
chromatographic conditions; flow rate (0.55 ml/min), column 
temperature (30 º C), autosampler temperature (10º C), injection 
volume (10 microliters), total run time (3.5 min), and column Ace 5 
C8 (50*2.1) mm. The retention time of hydrochlorothiazide with its 
internal standard was 0.34 min, amlodipine with its internal 
standard was 1. 4 min and valsartan with its internal standard was 
2.49 min. The HPLC system used was Agilents 1200 series coupled 
with API 4000, Applied Biosystems, MDS SCIEX detector; and 
computer system windows 7 professional. Data management was 
achieved by software Analyst 1.6. 
As recommended by FDA and EMEA bioanalytical method validation 
guidance [62, 65], plasma samples were analyzed for simultaneous 
determination of amlodipine, valsartan and hydrochlorothiazide 
after completing the clinical phase of the study (period II). Plasma 
samples obtained from each subject and for both periods (after test 
and reference products administration) were analyzed together, 
with the calibration curve including blank matrix and quality control 
(QC) samples, as one batch and in a single run. In each run, six 
quality control samples (dispersed evenly in a low-high and high-
low sequence throughout the batch) were analyzed. No calculation 
was done for measuring concentration by extrapolation below the 
lower limit of quantitation (LLOQ) and above the upper limit of 
quantitation (ULOQ) of the standard calibration curve.  
Pharmacokinetic (PK) analysis 
Plasma concentration-time data of each individual was analyzed by 
Kinetica software (v5.1) to calculate the PK parameters applying 
non-compartmental method [68]. The actual sampling times of 
blood were used for PK analysis. The PK parameter Cmax (maximum 
concentration of drug in plasma) was obtained directly from 
concentration versus time profile of each individual. The Tmax (time 
to attain Cmax) was obtained from concentration versus time curves. 
The AUC0-t (area under plasma concentration-time curve from time 
zero to tlast) was calculated by trapezoidal rule. The AUCt-∞ 
(extrapolated area under the plasma concentration-time curve from 
tlast to infinity was measured as Clast/λZ. The AUC0-∞ (total area under 
the plasma concentration-time curve from time zero to infinity) was 
calculated from the sum of AUC0-t+AUCt-∞. The λZ (first order terminal 
elimination rate constant) was estimated by linear regression of not 
less than 3 points of the last points at the terminal phase of the log-
concentration versus time plot of each subject. The T0.5 (first-order 
terminal elimination half-life) was calculated as 0.693/λZ. The Clast is 
the last measurable concentration of the drug which meets or 
exceeds the lower limit of quantification (LLOQ). The tlast is the time 
at which Clast occur. Since amlodipine is a drug of long terminal 
elimination half-life which is about 30-50 h, thus truncated AUC0-72 
was used, as per international guidance on bioavailability and 
bioequivalence concerning long elimination half-lives drugs [60-64]. 
Statistical analysis 
Statistical data analysis was achieved using kinetica software (v5.1). 
Descriptive statistics including arithmetic mean, geometric mean, 
standard deviation (±SD) and coefficient of variation (CV) were 
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done. For the purpose of bioequivalence testing, analysis of variance 
(ANOVA) and 90% confidence interval were applied. ANOVA was 
carried out to account for the effects of treatment, period, sequence 
and subjects nested in sequence on the PK parameters; Cmax, Tmax, 
AUC0-t, AUC0-∞, λZ and T1/2. Besides, ANOVA was also executed for the 
Ln-transformed values of the parameters; Cmax, AUC0-t, AUC0-∞ and 
(AUC0-72 h for amlodipine). The difference between PK parameters of 
the test (T) and the reference (R) drug products were declared 
statistically insignificant at 5% significance level (∝ = 0.05) when P ≥ 
0.05. Evaluation of bioequivalence was based on 90% confidence 
interval (CI) for geometric mean ratios T/R of the primary PK 
parameters used for bioequivalence evaluation (namely Cmax and 
AUC) of amlodipine, valsartan, and hydrochlorothiazide [65-67, 74]. 
Both products were concluded bioequivalent if 90% CI range 
between 80-125%, as recommended by international guidance [60-
64, 69]. The mean±SD for plasma concentrations-time data and the 
log-mean values were plotted in regular and semilog graph types, 
respectively using excel software.  
RERSULTS AND DISCUSSION 
Subjects demography  
As per study protocol, forty subjects were selected to participate in 
the study; however, one subject was dropped out before drug 
administration in period I due to clinical investigator decision. The 
demographic characteristics of the thirty-nine subjects participated 
in the study were as follow; mean age 31 y (range 18-46), mean 
weight 76 kg (range 54-95), mean height 1.73 meters (range 1.60-
1.90), and mean BMI 25.1 (range 18.7-29.7).  
Safety assessment 
The test and reference drug products were generally safe and well 
tolerated by all subjects. No incidence of adverse events or serious 
adverse events was registered during the study. All subjects who 
participated in the investigation (thirty-nine subjects) had 
successfully completed the study without any drop out or 
withdrawal. Clinical examinations and clinical laboratory test before 
subject discharge showed no clinically significant changes in the 
base line.  
Bioanalytical method validation 
The newly developed HPLC-MS/MS method used in the present 
investigation was rapid, sensitive, precise, accurate and 
selective/specific for simultaneous determination of amlodipine, 
valsartan, and hydrochlorothiazide in human plasma. Therefore, the 
current method can be reliably and successfully applied to analyze a 
large number of plasma samples obtained from patients receiving 
fixed-dose triple combination of these drugs for pharmacokinetic 
(PK), bioavailability (BA) and bioequivalence (BE) studies.  
The method was proved to be specific/selective since no 
interferences from endogenous plasma samples were found. 
Concerning amlodipine assay in plasma samples, the validation 
results are summarized as follow: the detection limits were 0.2-12 
ng/ml with a lower limit of quantification (LLOQ) of 0.2 ng/ml. The 
linearity and calibration curve range were established for 
concentrations range of 0.2-12 ng/ml with high coefficient of 
determination (R2) of 0.9987. The within run accuracy ranged 93.78-
101.89 % and for LLOQ it was 106.50%. The between run accuracy 
was 91.46-99.92% and it was107.47% for LLOQ. The within-run 
precision coefficient of variation (% CV) ranged 2.67-5.56, and for 
LLOQ it was 8.87 The between-run precision (%CV) was between 
3.98-5.78 and 7.63 for LLOQ. Besides, no considerable effect of the 
matrix on amlodipine and its internal standard was detected.  
The validation of valsartan assay in plasma samples are summarized 
as follow: the detection limits were 50-8000 ng/ml with LLOQ of 50 
ng/ml. The linearity and calibration curve range were established 
for the concentrations range of 50-8000 ng/ml with high (R2 
=0.9996). The within-run accuracy was between 95.73-102.07 % 
and for LLOQ it was 97.74%. The between-run accuracy was 
between 97.07-99.92 %, and it was 103.04% for LLOQ. The within-
run precision (% CV) was between 1.11-4.01, and for LLOQ it was 
3.43. The between-run precision (%CV) ranged 2.43-3.60, and it was 
5.38 for LLOQ. Moreover, no remarkable effect of the matrix on 
valsartan and its internal standard was found.  
The main validation characteristics of hydrochlorothiazide assay in 
plasma samples are: the detection limits were 2.0-250.0 ng/ml with 
LLOQ of 2 ng/ml. The linearity and calibration range was 2.0-250.0 
ng/ml and R2 was high (0.9991). The within-run accuracy was 
between104.28-108.14 %, and for LLOQ it was 100.85%. The 
between-run accuracy ranged100.31-103.99 %, and it was 106.04 % 
for LLOQ. The within-run precision (CV %) was between 1.15-8.0 
and for LLOQ it was 5.97. The between-run precision (CV %) was 
between 4.70-5.94, and 11.40 for LLOQ. Furthermore, No significant 
effect of the matrix on hydrochlorothiazide and its internal standard 
was observed. 
The results of stability studies of the analytes (amlodipine, valsartan, 
and hydrochlorothiazide) in the biological matrix (plasma), and the 
stability of the analytes and their internal standards in the stock and 
working solutions and in extracts under the entire period of storage 
and processing conditions were within the acceptable ranges. The 
long-term stability of the analytes at-20º C covered the period from 
the first blood sample withdrawal from the subjects and until the 
date of last sample assay of the analytes. The long-term stability for 
recovered amlodipine was 99.42-101.00%, for valsartan 86.79-
99.87%, and for hydrochlorothiazide 93.26-96.75% which is very 
acceptable.  
Plasma concentrations of the drugs 
The mean±SD for plasma concentrations-time data and the 
corresponding log-mean values for amlodipine, valsartan and 
hydrochlorothiazide are depicted in regular and semilog graph types 
as shown in fig. 1-6. The mean plasma concentration-time profiles of 
the test product were almost similar and superimposable with the 
reference product for the three components (amlodipine, valsartan, 
and hydrochlorothiazide) suggesting equivalent absorption and 
disposition (distribution and elimination) characters (fig. 1-6).  
The drugs amlodipine, valsartan, and hydrochlorothiazide were not 
detected in any plasma sample obtained before drug products 
administration (zero/blank sample) of any subject which insures the 
absence of carryover effects, and indicating that a washout period of 
two weeks is sufficient for almost complete removal of the drugs 
from the body. Thus, reliable estimation of concentrations of these 
drugs in plasma and their pharmacokinetics could be guaranteed.  
The following blood sampling strategy (0, 0.33, 0.66, 1.0, 1.33, 1.66, 
2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 
14, 16, 24, 48 and eventually at 72 h post dosing) performed in this 
investigation was adequate enough to show the entire 
pharmacokinetic behaviors of the drugs (amlodipine, valsartan, and 
hydrochlorothiazide) including absorption, distribution and 
elimination. The sampling schedule was early enough to insure 
reliable estimation of the absorption phase/rate, and the onset of 
appearance of the drugs in plasma. The sampling was very frequent 
in order to detect and show any fluctuation (if any) in the 
concentration of the investigated drugs in plasma. Besides, the 
sampling was for an adequate time (72 h post dosing) in order to 
insure reliable estimation of the terminal elimination half-lives of 
valsartan, and hydrochlorothiazide. Concerning amlodipine, since it 
is long half-life drug (30-50 h), thus, blood sampling for 72 h post 
dosing is acceptable as recommended by international guidance for 
bioequivalence [60-64].  
After administration of the test product, amlodipine was detected in 
plasma samples after 40 min post dosing in 25 subjects out of the 
total 39 subjects participated in the study. The same observations 
were noticed after administration of the reference product in which 
the drug was detected in 21 subjects after 40 min post dosing. The 
drug was detected in all subjects and for both products after 1 hour 
after administration. This indicates the close similarity in the rate of 
absorption of amlodipine from both products. Besides, this finding 
demonstrates rapid appearance of the drug in the systemic 
circulation after oral administration. Interestingly, similar 
absorption behaviors were also noticed for valsartan and 
hydrochlorothiazide and for both products. 
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Fig. 1: Amlodipine plasma concentrations-time profile after a single dose administration of the reference product (Exforge HCT® 
containing fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-nine healthy male 
adult subjects. Data points represent mean±SD (N=39) 
 
 
Fig. 2: Amlodipine mean log plasma concentrations-time profile after a single dose administration of the reference product (Exforge HCT® 




Fig. 3: Valsartan plasma concentrations-time profile after a single dose administration of the reference product (Exforge HCT® containing 
fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-nine healthy male adult 
subjects. Data points represent mean±SD (N=39) 
 
 
Fig. 4: Valsartan mean log plasma concentrations-time profile after a single dose administration of the reference product (Exforge HCT® 
containing fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-nine healthy male 
adult subjects 
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Fig. 5: Hydrochlorothiazide plasma concentrations-time profile after a single dose administration of the reference product (Exforge HCT® 
containing fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-nine healthy male 
adult subjects. Data points represent mean±SD (N=39) 
 
 
Fig. 6: Hydrochlorothiazide mean log plasma concentrations-time profile after a single dose administration of the reference product 
(Exforge HCT® containing fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-
nine healthy male adult subjects 
 
Pharmacokinetic (PK) characteristics 
The average PK parameters obtained from PK analysis of the 
individual plasma concentration versus time data of the reference 
and the test products for amlodipine, valsartan and 
hydrochlorothiazide are summarized in tables 1-3. The results 
indicate that both products demonstrate almost similar PK 
behaviors. The primary PK parameters which reflect the rate of drug 
absorption (namely Cmax and Tmax) indicates that both products 
exhibit almost similar absorption behaviors. Besides, the primary PK 
parameters which reflect the extent of drug absorption and the 
systemic exposure (namely Cmax and AUC) were approximately 
identical. Moreover, the terminal phase/decay of the concentration-
time profiles of both products are parallel indicating similar 
elimination behaviors of both products. Thus, both test and 
reference formulations are equivalent in term of absorption from 
GIT (rate and extent) and disposition regarding all components 
amlodipine, valsartan, and hydrochlorothiazide. 
Moreover, the interindividual variations in the PK parameters of 
amlodipine (table 1), valsartan (table 2) and hydrochlorothiazide (table 
3) of the test product are almost similar to the corresponding 
parameters of the reference product. Valsartan (table 2) demonstrated 
high intersubject variability (%CV about 50%) in all PK parameters. 
Hydrochlorothiazide elucidated %CV range of 20-50% (table 2). 
Whereas, amlodipine showed relatively low %CV of about 20% (table 1).  
For both valsartan (table 2) and hydrochlorothiazide (table 3), the % 
AUCextrapolated  
(AUCt-∞/AUC0-∞ x 100) in all subjects and for both test and reference 
products had very low contribution to the total AUC since % 
AUCextrapolated was less than 10%. Thus, blood sampling time for 72 h 
post dosing, and a lower limit of quantitation of 50 ng/ml for 
valsartan and 2 ng/ml for hydrochlorothiazide used in this study are 
adequate enough for PK, BA and BE studies of these drugs. 
Many PK, BA, and BE studies were conducted for amlodipine 
administered alone [24, 26, 30-38], valsartan alone [39-41] or 
hydrochlorothiazide alone [43, 44]. Besides, PK, BA, and BE 
investigations were also achieved for combination of two or three drugs, 
such as amlodipine with olmesartan [25], amlodipine with valsartan [27-
29], or valsartan with hydrochlorothiazide [14, 42]. However, very 
limited PK, BA or BE information is presented in literature after a single 
dose administration of fixed dose combination of amlodipine, valsartan, 
and hydrochlorothiazide tablet [1]. Comparing the results obtained 
from the current investigation (table 1) with that presented in 
literature after a single oral doses of amlodipine show some 
differences in Cmax and AUC, whereas good similarity is observed for 
Tmax and T1/2 The mean Cmax found in the current study is about 5.0 
ng/ml (table 1). The average Cmax obtained in other investigations 
are; about 6 ng/ml [24, 27, 29, 31, 32], 7 ng/ml [25, 30], 4 ng/ml [26, 
36], 2 ng/ml [33], 5 ng/ml [34], and about 8 ng/ml [35]. The average 
AUC0-72 h calculated in this study is approximately 180 ng. hr/ml 
(table 1). Previous investigations showed mean values of about 216 
ng. hr/ml [24], 245 ng. hr/ml [25], and 190 ng. hr/ml [27]. The 
higher differences in average Cmax values found between studies 
relative to the differences in AUC is expected from PK point of view 
since Cmax is a single data point in comparison to AUC which represent 
the whole concentration-time profile, in addition to individual 
variations. The average Tmax and T1/2 found in the current study are 
about 7 and 40 h, respectively (table 1); which are almost similar to 
that obtained from many previous investigations [24-35, 37].  
The mean Cmax of valsartan found in this investigation is about 3000 
ng/ml and the mean total AUC is about 20000 ng. hr/ml (table 1). The 
approximate Cmax and total AUC values presented in other studies were 
as follow: 4000 ng/ml and 43000 ng. hr/ml [14], 5000 ng/ml and 
33000 ng. hr/ml [39], 3500 ng/ml and 23000 ng. hr/ml [27], 5000 
ng/ml and 35000 ng. hr/ml [28], 3800 ng/ml and 28000 ng. hr/ml 
[29], 2000 ng/ml and 24000 [40]. It is obvious from these results that 
valsartan exhibit some individual variation in these PK parameters. On 
the other hand, The average Tmax and T1/2 found in this study are about 
3 and 10 h, respectively (table 1); which are almost similar to that 
obtained from many other investigations [14, 27-29, 39, 40].  
The average Cmax of hydrochlorothiazide found in the current study 
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is about 130 ng/ml and the average total AUC about 1000 ng/ml. 
The reported average Cmax were about 150 ng/ml [14] and 170 
ng/ml [44], the reported total AUC were approximately 1800 ng. 
hr/ml [14] and 1200 ng. hr/ml [44]. This difference in these 
parameters is attributed mainly to individual variability. The 
average Tmax and T1/2 obtained in this study are about 2 and 9 h, 
respectively which are almost identical to that presented in a 
previous study [14].  
 
Table 1: Pharmacokinetic parameters of Amlodipine after a single dose administration of the reference product (Exforge HCT® containing 
fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg tablet) and a test product to thirty-nine healthy male 
adult subjects 
Parameter Test product Reference product 
C max 
(ng/ml) 
Geometric Mean 5.408 5.214 
Arithmetic Mean 5.491 5.302 
±SD (1) 0.9940 0.9529 
CV % (2) 18.10 17.97 
N (3) 39 39 
AUC 0-72 
(ng. hr/ml) 
Geometric Mean 186.145 179.468 
Arithmetic Mean 190.083 182.867 
±SD 40.2090 34.5963 
CV % 21.15 18.92 
N 39 39 
T max 
(hrs.) 
Median 7.00 7.00 
Range 5.0-10.0 4.0-16.0 
Arithmetic Mean 6.83 6.96 
±SD 1.695 2.199 
CV % 24.80 31.58 









(1/hr.) Arithmetic Mean 0.01864 0.01814 




 CV % 20.00 24.26 




Arithmetic Mean 38.69 41.16 
±SD 8.046 13.898 
CV % 20.80 33.77 
N 39 39 
(1)SD=StandardDeviation.(2)CV%=CoefficientofVariation.(3)N=Numberofsubjects 
 
Table 2: Pharmacokinetic parameters of Valsartan after a single dose administration of the reference product (Exforge HCT® containing fixed-
dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-nine healthy male adult subjects 
Parameter Test product Reference product 
C max 
(ng/ml) 
Geometric Mean 2545.442 2637.339 
Arithmetic Mean 2981.250 3032.849 
±SD (1) 1593.5828 1622.4859 
CV % (2) 53.45 53.50 
N (3) 39 39 
AUC 0-t 
(ng. hr/ml) 
Geometric Mean 18019.463 17450.671 
Arithmetic Mean 20809.792 20098.508 
±SD 11259.1828 10785.8111 
CV % 54.11 53.66 
N 39 39 
AUC 0-∞ 
(ng. hr/ml) 
Geometric Mean 19046.778 19337.613 
Arithmetic Mean 21916.131 21825.207 
±SD 11661.7626 10866.0725 
CV % 53.21 49.79 
N 38 37 
T max 
(hrs.) 
Median 3.00 3.00 
Range 1.33-7.0 1.0-5.0 
Arithmetic Mean 2.98 2.90 
±SD 1.220 1.120 
CV % 40.90 38.62 
N 39 39 
Lz 
(1/hr.) 
Geometric Mean 0.10554 0.11103 
Arithmetic Mean 0.11504 0.11483 
±SD 0.042384 0.027181 
CV % 36.84 23.67 
N 38 37 
T ½ 
(hrs.) 
Arithmetic Mean 7.50 6.52 
±SD 5.164 2.261 
CV % 68.85 34.68 
N 38 37 
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Table 3: Pharmacokinetic parameters of Hydrochlorothiazide after a single dose administration of the reference product (Exforge HCT® 
containing fixed-dose combination of Amlodipine 10 mg, Valsartan 160 mg, and HCT 25 mg) and a test product to thirty-nine healthy male 
adult subjects 
Parameter Test product Reference product 
C max 
(ng/ml) 
Geometric Mean 122.304 129.257 
Arithmetic Mean 127.235 133.435 
±SD 36.1699 34.6043 
CV %  28.43 25.93 
N  39 39 
AUC 0-t 
(ng. hr/ml) 
Geometric Mean 849.526 857.493 
Arithmetic Mean 874.028 888.595 
±SD 221.4740 245.0147 
CV % 25.34 27.57 
N 39 39 
AUC 0-∞ 
(ng. hr/ml) 
Geometric Mean 926.286 938.198 
Arithmetic Mean 950.370 968.633 
±SD 224.1029 248.9472 
CV % 23.58 25.70 
N 38 39 
T max 
(hrs.) 
Median 2.00 1.66 
Range 0.66-6.5 1.0-5.0 
Arithmetic Mean 2.24 1.92 
±SD 1.142 0.756 
CV % 51.06 39.46 
N 39 39 
Lz 
(1/hr.) 
Geometric Mean 0.08100 0.07561 
Arithmetic Mean 0.08231 0.07694 
±SD 0.014778 0.014284 
CV % 17.95 18.56 
N 38 39 
T ½ 
(hrs.) 
Arithmetic Mean 8.70 9.34 
±SD 1.614 1.875 
CV % 18.55 20.08 
N 38 39 
 
Table 4: Statistical analysis of pharmacokinetic parameters 
Parameter Ratio of geometric mean (%) 90% confidence interval (%) F(1)(%) 
C max AUC 0-t AUC 0-∞ C max AUC 0-t AUC 0-∞ AUC 0-t AUC 0-∞ 




-  103.9 - 






 103.5 100.4 






 98.4 98.1 
(1)F: Ratio of arithmetic means (relative bioavailability)  
 
CONCLUSION 
The current investigation demonstrated that the pharmacokinetic 
characteristics of a newly developed generic tablet containing fixed-
dose combination of amlodipine/valsartan/hydrochlorothiazide 
(10/160/25 mg) are clearly similar to the brand product Exforge 
HCT® tablet manufactured by Novartis, Switzerland. The rate and 
extent of bioavailability of both products are identical. The range of 
90% CI of Cmax and AUC for amlodipine, valsartan, and hydro-
chlorothiazide were well within BE acceptance range of 80-125. Thus, 
both products is bioequivalent and clinically interchangeable. 
Besides, the present study present outline information of a newly 
developed HPLC-MS/MS bioanalytical method for simultaneous 
determination of amlodipine, valsartan, and hydrochlorothiazide 
in human plasma after administration of fixed-dose combination 
tablet containing amlodipine/ valsartan/hydrochlorothiazide 
(10/160/25 mg). The method is validated according to FDA and 
EMEA bioanalytical method validation guidance. The method is 
proved to be rapid, sensitive, precise, accurate and specific/ 
selective. Therefore, this method can be successfully applied for 
measuring large number of plasma samples containing these drugs 
together to be used for pharmacokinetic, bioavailability, and 
bioequivalence studies.  
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